Accenture Announces Collaboration with Bayer to Streamline Drug Development Processes through INTIENT Clinical Platform
September 16 2019 - 04:59AM
Business Wire
Accenture (NYSE: ACN) has announced a collaboration with Bayer
to implement the Accenture INTIENT Clinical platform to help
simplify and speed its drug development processes. The platform,
which went live at Bayer earlier this year, brings internal and
external clinical data together with Oracle cloud-based
technologies into a single data management and warehousing
platform, creating actionable insights to accelerate drug
development and improve patient outcomes.
The Accenture INTIENT Clinical platform is part of Accenture
INTIENT™ and builds upon Accenture’s market-proven platforms for
research, clinical development, pharmacovigilance and patient
services. It rapidly integrates new technology, advanced analytics
and applied intelligence to support the delivery of patient
treatments.
Bayer has also joined the Life Sciences Cloud Coalition, which
was developed to enable pre-competitive collaboration between
pharmaceutical companies with the goal to more quickly and
cost-effectively advance clinical development. The coalition brings
together Oracle Health Sciences and R&D leaders from around the
world to drive innovation and digitally enable the R&D
function.
Mike Stapleton, a managing director in Accenture’s Life Sciences
practice, said: “We are excited to work with Bayer to provide new
insights on their clinical trials, so they can bring the important
treatments they develop to patients faster and with the highest
quality. The future of R&D is bright when leading organizations
come together to solve for patients’ greatest needs.”
The INTIENT Clinical platform was developed through an alliance
between Accenture and Oracle. It combines Accenture’s proven
implementation experience with solutions such as the Oracle Health
Sciences Data Management Workbench and Oracle Life Sciences Data
Hub. Together, these solutions generate high-quality, reliable data
from clinical trials and reduce the time, effort and cost needed to
take drugs from development to market. The Oracle solutions are
powered by Oracle Cloud Infrastructure, supported with Oracle
Managed Cloud Services.
“We welcome Bayer as a new member of the Life Sciences Cloud
Coalition and to the Oracle Health Sciences Data Management
Workbench family. Their perspective and experience will be
invaluable in the advancement of clinical development for the
entire industry,” said Steve Rosenberg, senior vice president and
general manager, Oracle Health Sciences.
About Accenture
Accenture is a leading global professional services company,
providing a broad range of services and solutions in strategy,
consulting, digital, technology and operations. Combining unmatched
experience and specialized skills across more than 40 industries
and all business functions — underpinned by the world’s largest
delivery network — Accenture works at the intersection of business
and technology to help clients improve their performance and create
sustainable value for their stakeholders. With 469,000 people
serving clients in more than 120 countries, Accenture drives
innovation to improve the way the world works and lives. Visit us
at www.accenture.com.
Trademarks
Oracle and Java are registered trademarks of Oracle and/or its
affiliates. Other names may be trademarks of their respective
owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190916005107/en/
Lara Wozniak Accenture +1 858 252 8208
lara.wozniak@accenture.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From Mar 2023 to Mar 2024